EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Role of ctDNA in the Management of Non-Small-Cell Lung Cancer in the AI and NGS Era

Jacopo Costa, Alexandro Membrino iD, Carol Zanchetta, Simona Rizzato, Francesco Cortiula iD, Ciro Rossetto, Giacomo Pelizzari, Giuseppe Aprile, Marianna Macerelli

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252413669 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Jacopo Costa und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine (DAME), University of Udine, 33100 Udine, Italy. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Carcinoma, Non-Small-Cell Lung, High-Throughput Nucleotide Sequencing, Lung Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liquid biopsy (LB) involves the analysis of circulating tumour-derived DNA (ctDNA), providing a minimally invasive method for gathering both quantitative and qualitative information. Genomic analysis of ctDNA through next-generation sequencing (NGS) enables comprehensive genetic profiling of tumours, including non-driver alterations that offer prognostic insights. LB can be applied in both early-stage disease settings, for the diagnosis and monitoring of minimal residual disease (MRD), and advanced disease settings, for monitoring treatment response and understanding the mechanisms behind disease progression and tumour heterogeneity. Currently, LB has limited use in clinical practice, primarily due to its significant costs, limited diagnostic yield, and uncertain prognostic role. The application of artificial intelligence (AI) in the medical field is a promising approach to processing extensive information and applying it to individual cases to enhance therapeutic decision-making and refine risk assessment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNACarcinoma, Non-Small-Cell LungHigh-Throughput Nucleotide SequencingLung NeoplasmsArtificial IntelligenceBiomarkers, TumorHumansLiquid BiopsyPrognosis

Stichwörter der Autor:innen

NGSNSCLCartificial intelligencectDNAliquid biopsy

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medicine (DAME), University of Udine, 33100 Udine, Italy.
  • Department of Oncology, University Hospital of Udine, 33100 Udine, Italy.
  • Department of Respiratory Medicine, Maastricht University Medical Centre, GROW School for Oncology and Reproduction, 6229 ER Maastricht, The Netherlands.

ORCID-Profile: Alexandro Membrino, Francesco Cortiula

Zitieren

APA

Costa, J., Membrino, A., Zanchetta, C., Rizzato, S., Cortiula, F., Rossetto, C., Pelizzari, G., Aprile, G., & Macerelli, M. (2024). The Role of ctDNA in the Management of Non-Small-Cell Lung Cancer in the AI and NGS Era. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252413669

Vancouver

Costa J, Membrino A, Zanchetta C, Rizzato S, Cortiula F, Rossetto C, et al. The Role of ctDNA in the Management of Non-Small-Cell Lung Cancer in the AI and NGS Era. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252413669

BibTeX
@article{Costa2024,
  author = {Costa, Jacopo and Membrino, Alexandro and Zanchetta, Carol and Rizzato, Simona and Cortiula, Francesco and Rossetto, Ciro and Pelizzari, Giacomo and Aprile, Giuseppe and Macerelli, Marianna},
  title = {The Role of ctDNA in the Management of Non-Small-Cell Lung Cancer in the AI and NGS Era},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252413669}
}
Kostenlos starten →